FDA approved Jetrea (ocriplasmin)

Jetrea (ocriplasmin) is an alpha-2 antiplasmin reducer used specifically in the treatment of symptomatic vitreomacular adhesion.

The recommended dose is 0.125 mg (0.1 mL of the diluted solution.) It is administered by intravitreal injection to the affected eye once as a single dose.

Jetrea is also used in the treatment of vitreous floaters, conjunctival hemorrhage, eye pain, photopsia, blurred vision, macular hole, reduced visual acuity, visual impairment and retinal edema.


Popular posts from this blog

Facial muscles